arrow
J

Jörg Trojan

akademie fur angewandte bewegungswissenschaften ggmbh
H指数:39
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial)

II期随机试验的初步结果,该试验比较了TACE联合伊立替康和丝裂霉素C与多柔比星治疗中期HCC的效果(IRITACE试验)。

2024-09-010
PRE
Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study

Nab-紫杉醇/吉西他滨联合或不联合表观遗传靶向治疗,随后进行durvalumab和lenalidomide巩固性免疫靶向治疗,用于晚期胰腺导管腺癌患者:SEPION/AIO-PAK-0118 I/II期研究的结果

2024-09-010
PRE
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial
2024-04-040
PRE
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
2024-03-085
OAAI
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

在前瞻性队列研究中检测HCC的新型算法评分 (GAAD) 的开发和临床验证

2023-11-0117
OAAI
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
2020-10-2311
OAAI
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
2020-10-1729
OAAI
Evaluating assumptions of scales for subjective assessment of thermal environments - Do laypersons perceive them the way, we researchers believe?

评估热环境主观评估量表的假设-我们研究人员认为,外行人是否以这种方式感知它们?

2020-03-0177
OAAI
The Scales Project, a cross-national dataset on the interpretation of thermal perception scales
2019-11-260
OAAI